Biosergen publishes 2022 annual report
Wednesday, May 10, 2022: Biosergen AB (“Biosergen” or the “Company”) hereby announces that the 2022 annual report is available on the company website (www.biosergen.net)Biosergen CEO Peder M. Andersen commented: "We are pleased to present Biosergen's annual report for 2022. The most important event during the year was the successfully repeated dose escalation in our Phase I trial in Australia, which has since been successfully completed earlier this year. The trial was successful in both the single and in the multiple ascending dose part and proved BSG005 to be safe and well tolerated with